The prognostic value of the hypoxia markers CA IX and GLUT I and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy

BMC Cancer

Volumn 5, Issue , 2005, Pages

  De Schutter, Harlinde ^a   Landuyt, Willy ^a   Verbeken, Erik ^a   Goethals, Laurence ^a   Hermans, Robert ^a   Nuyts, Sandra ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; CISPLATIN; GLUCOSE TRANSPORTER 1; INTERLEUKIN 6; UNCLASSIFIED DRUG; VASCULOTROPIN; CA9 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MICROENVIRONMENT; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; RADIOSENSITIVITY; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; BLOOD; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; HEAD AND NECK TUMOR; METABOLISM; MULTIVARIATE ANALYSIS; PERFUSION; TIME; TREATMENT OUTCOME;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MULTIVARIATE ANALYSIS; PERFUSION; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 26844468059     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-42     Document Type: Article

References (30)

1. Bussink J, Kaanders JH, van der Kogel AJ: Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 2003, 67:3-15.
2. Hermans R, Meijerink M, Van den BW, Rijnders A, Weltens C, Lambin P: Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003, 57:1351-1356.
3. Brizel DM, Dodge RK, Clough RW, Dewhirst MW: Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999, 53:113-117.
4. Nordsmark M, Overgaard J: A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000, 57:39-43.
5. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I, West C: Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001, 7:928-934.
6. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, Gatter KC, Harris AL: Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001, 7:3399-3403.
7. Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, Bartenstein P, Wagner W, Whiteside TL: Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 2003, 97:1015-1024.
8. Mineta H, Miura K, Takebayashi S, Misawa K, Araki K, Misawa Y, Ueda Y: Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma. Anticancer Res 2002, 22:3489-3494.
9. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ: Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001, 158:905-919.
10. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL: Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000, 60:7075-7083.
11. Mellanen P, Minn H, Grenman R, Harkonen P: Expression of glucose transporters in head-and-neck tumors. Int J Cancer 1994, 56:622-629.
12. Dunst J, Stadler P, Becker A, Kuhnt T, Lautenschlager C, Molls M, Haensgen G: Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahlenther Onkol 2001, 177:469-473.
13. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16:4604-4613.
14. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL, Van Waes C: Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999, 5:1369-1379.
15. Teknos TN, Cox C, Yoo S, Chepeha DB, Wolf GT, Bradford CR, Carey TE, Fisher SG: Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck 2002, 24:1004-1011.
16. St John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, Shi W, Qi F, Wu B, Sinha U, Jordan R, Wolinsky L, Park NH, Liu H, Abemayor E, Wong DT: Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004, 130:929-935.
17. Muraoka K, Shimizu K, Sun X, Zhang YK, Tani T, Hashimoto T, Yagi M, Miyazaki I, Yamamoto K: Hypoxia, but not reoxygenation, induces interleukin 6 gene expression through NF-kappa B activation. Transplantation 1997, 63:466-470.
18. Srivani R, Nagarajan B: A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int J Gynecol Cancer 2003, 13:331-339.
19. Chung YC, Chang YF: Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 2003, 83:222-226.
20. Michalaki V, Syrigos K, Charles P, Waxman J: Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004, 90:2312-2316.
21. Brouazin-Jousseaume V, Guitton N, Legue F, Chenal C: GSH level and IL-6 production increased in Sertoli cells and astrocytes after gamma irradiation. Anticancer Res 2002, 22:257-262.
22. Miyamoto Y, Hosotani R, Doi R, Wada M, Ida J, Tsuji S, Kawaguchi M, Nakajima S, Kobayashi H, Masui T, Imamura M: Interleukin-6 inhibits radiation induced apoptosis in pancreatic cancer cells. Anticancer Res 2001, 21:2449-2456.
23. Tamatani T, Azuma M, Ashida Y, Motegi K, Takashima R, Harada K, Kawaguchi S, Sato M: Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int J Cancer 2004, 108:912-921.
24. Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J: A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992, 187:620-626.
25. Vaupel P, Kelleher DK, Hockel M: Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001, 28:29-35.
26. Tartour E, Deneux L, Mosseri V, Jaulerry C, Brunin F, Point D, Validire P, Dubray B, Fridman WH, Rodriguez J: Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study. Cancer 1997, 79:1401-1408.
27. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, Gatter KC, Johnson PJ, Harris AL: Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002, 8:2595-2604.
28. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, de Wilde PC, Bussink J, Raleigh JA, van der Kogel AJ: Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002, 62:7066-7074.
29. Dietz A, Rudat V, Conradt C, Weidauer H, Ho A, Moehler T: Prognostic relevance of serum levels of the angiogenic peptide bFGF in advanced carcinoma of the head and neck treated by primary radiochemotherapy. Head Neck 2000, 22:666-673.
30. Jelkmann W: Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001, 47:617-623.